Our findings support further exploration of pharmacologic inhibition of CLK1 as a potential new treatment for obesity associated diabetes, beyond oncology, Duchenne muscular dystrophy and Alzheimer’s disease. Here, CLK1 is linked to early-onset autosomal dominant Alzheimer disease.